斯塔默访华引来重磅投资，阿斯利康宣布将于2030年前在中国投资超千亿元

Group 1 - The UK Prime Minister Starmer's visit to China marks the first such visit in 8 years, accompanied by over 50 executives and representatives from various sectors including finance, pharmaceuticals, manufacturing, and culture [1][2] - AstraZeneca's CEO and GSK's Chairman are part of the delegation, highlighting the focus on the pharmaceutical industry [1] - China is becoming a key hub for multinational pharmaceutical companies due to its comprehensive industrial support, vast clinical resources, and improving regulatory environment [1] Group 2 - AstraZeneca plans to invest over 100 billion RMB (approximately 15 billion USD) in China by 2030 to enhance its drug production and R&D capabilities [1][2] - This investment aims to strengthen AstraZeneca's capabilities in cell therapy and radiolabeled drugs, benefiting patients with cancer, blood diseases, and autoimmune disorders [1] - The investment will cover the entire value chain from drug discovery to clinical development and manufacturing, collaborating with leading biotech companies to globalize Chinese innovations [1] Group 3 - AstraZeneca's investment will deepen its R&D presence in China, including global strategic R&D centers in Beijing and Shanghai [2] - The company will upgrade existing production bases in Wuxi, Taizhou, Qingdao, and Beijing, with plans for new production facilities to be announced [2] - The investment is expected to increase AstraZeneca's workforce in China to over 20,000 employees and create thousands of new jobs within the healthcare ecosystem [2]